Skip to content. | Skip to navigation

Change your language:
  • Pca3

    Sections

    Suspected PCa pre-biopsy

    Suspected PCa Pre-biopsy (abnormal DRE / elevated PSA)

    1. Cancer Risk Calculator for prostate cancer

    Prostate biopsy close

    This risk calculator predicts for men with suspected PCa based on an abnormal DRE and/or elevated PSA the probability of a positive biopsy, including the probability of a high grade (high Gleason score) biopsy. It takes into account

    1. race
    2. age
    3. family history of PCa
    4. DRE outcome
    5. PSA
    6. whether or not a prior biopsy was negative.

    This risk calculator is based on the US Prostate Cancer Prevention Trial (PCPT) in which 5519 older men with a relatively low PSA (≤ 3 ng/mL) who did not receive treatment for 7 years had a 6-core biopsy.

    More information: http://www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp

    Back to top

    2. Prostate Risk Indicator

    This risk calculator currently consists of 4 prostate risk indicators. The first 3 predict the probability of a positive biopsy. They take into account

    Risk indicator 1

    1. age
    2. family history of PCa
    3. frequency of urinary symptoms

    Risk indicator 2

    1. PSA

    Risk indicator 3 (you very likely need to consult a physician to use indicator 3)

    1. PSA
    2. transrectal ultrasonography (TRUS) outcome
    3. DRE outcome
    4. prostate volume

    The Prostate Risk Indicator is based on data from 6288 Dutch men aged 55-74 years living in Rotterdam and participating in the European Randomized Study of Screening for Prostate Cancer (ERSPC). These men were tested for PSA in their blood and for any prostate abnormalities by DRE and TRUS and were subsequently followed-up over time.

    More information: http://www.prostate-riskindicator.com/via.html

    Back to top
    Questions & Answers

    FAQFind the answer to all your questions about PCA3 in the frequently asked questions section

    Risk calculators

    calculatorUse tools from research institutions developed to predict the risk of prostate cancer